Form 4: Century Therapeutics SVP Granted Equity Awards

Century Therapeutics' SVP of Finance & Operations, Douglas Carr, received 110,000 restricted stock units and options for 225,000 shares.

Summary

• Douglas Carr, SVP Finance & Operations of Century Therapeutics, Inc. (IPSC), was granted 110,000 Restricted Stock Units (RSUs) on February 2, 2026.
• Each RSU represents a contingent right to receive one share of common stock, with no acquisition price.
• The RSUs vest 25% on February 2, 2027, and the remaining 75% vests quarterly over the subsequent three years, contingent on continued service.
• Carr was also granted options to purchase 225,000 shares of common stock on February 2, 2026, with an exercise price of $1.84 per share.
• These options vest 25% on February 2, 2027, and the remaining 75% vests in 36 equal monthly installments thereafter, contingent on continued service.
• The options have an expiration date of February 2, 2036.
• Following these transactions, Carr beneficially owns 514,874 shares of common stock directly and 225,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies a standard executive compensation practice that aligns management incentives with shareholder interests, without indicating any immediate operational or financial performance changes.

Positives

• The equity grants align the interests of a key executive, Douglas Carr, with those of shareholders, incentivizing long-term company performance.
• The grants represent a commitment to retaining senior management, which is crucial for stability and strategic execution.

Negatives

• The grants do not represent an immediate cash infusion for the company.
• The vesting schedules tie a significant portion of the executive's compensation to continued service, which could be a disincentive for immediate liquidity.

Risks

• The value of the RSUs and stock options is subject to the future performance and market price of Century Therapeutics' common stock.
• If the reporting person's service terminates before vesting dates, unvested RSUs and options may be forfeited.
• Stock options carry the risk that the market price may not exceed the exercise price, rendering them worthless.

Future Outlook

The vesting schedules for the RSUs and stock options extend several years into the future, indicating a long-term incentive structure for the SVP of Finance & Operations, contingent on continued service and potential future stock price appreciation.

Management Comments

• Douglas Carr, SVP Finance & Operations, received a grant of 110,000 Restricted Stock Units and options to purchase 225,000 shares of common stock.

Industry Context

StockSavvy.ai notes that equity grants, such as RSUs and stock options, are a common and standard practice in the biotechnology and pharmaceutical industries. These compensation tools are widely used to attract, retain, and motivate key executives by aligning their financial interests with the long-term performance and shareholder value creation of the company.

Comparison to Industry Standards

• Equity grants to senior executives are a standard compensation practice across the biotech and broader corporate landscape.
• The specific number of shares and vesting schedules are typically determined by company-specific compensation policies, executive role, and market benchmarks for similar positions, though this filing does not provide details for direct comparison to specific companies or projects.

Related Party Transactions

• None beyond the disclosed equity grants to an officer as part of their compensation package.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the interests of a key executive with shareholders, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing, but it reflects the company's executive compensation strategy.

Next Steps

• The RSUs will begin vesting on February 2, 2027, with subsequent quarterly vesting over three years.
• The stock options will begin vesting on February 2, 2027, with subsequent monthly vesting over 36 months.
• Douglas Carr may exercise the vested stock options at the specified exercise price of $1.84 per share at any time before the expiration date of February 2, 2036.

Key Dates

Keywords

Century Therapeutics, IPSC, Douglas Carr, Form 4, Restricted Stock Units, Stock Options, Equity Grant, Insider Transaction, Executive Compensation